For FQHCs, "supply chain" means something different than it does for a hospital.
Most supply chain conversations in healthcare start from a hospital’s vantage point: GPO contracts, purchased services, clinical supply categories. That framing doesn’t map cleanly onto a federally qualified health center. For the most part, FQHCs don’t have access to the same large hospital group purchasing organizations that negotiate clinical supply and pharmaceutical pricing at scale. Instead, most rely on smaller, regional group purchasing programs run through state and regional primary care associations, covering a narrower and more fragmented set of categories.
That difference matters, because it means the supply chain risk that deserves an FQHC’s attention isn’t the same one a hospital is managing. For most health centers, it’s 340B.
The 340B Drug Pricing Program is a federal program that requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at a significant discount to eligible healthcare organizations, known as covered entities.* FQHCs qualify as covered entities automatically because of their federal designation.
The idea behind the program is straightforward: the savings generated through 340B are meant to be reinvested into serving patients, stretching limited resources further for the low-income and uninsured populations these organizations serve. For a health center operating on thin margins and grant funding, those savings often aren’t a bonus. They’re part of how the organization stays financially viable.
Nearly every FQHC in the country depends on it in some form, and the reason is straightforward: FQHCs serve as the health home for more than 30 million people, including 1 in 5 Medicaid beneficiaries and 1 in 3 people living in poverty nationwide.**
That’s exactly what makes 340B a supply chain issue and not just a pharmacy or finance issue. Accessing those savings means managing a web of vendor relationships, and how well that web is governed determines whether the savings are fully realized or quietly leak away.
Most FQHCs access 340B through what’s known as the contract pharmacy model: contracting with outside retail pharmacies to dispense 340B-priced drugs, rather than operating an in-house pharmacy themselves. It’s the most common approach because it’s the easiest to stand up. It also comes with real limitations, including less coordinated patient care and lower captured savings compared to an in-house pharmacy, and it depends on a set of vendor relationships that need active management: the contract pharmacies themselves, third-party administrators who help manage claims and compliance, and the wholesalers and manufacturers whose policies govern how the discounts actually flow.***
Each of those relationships carries its own agreement, its own compliance terms, and its own risk if it’s not actively tracked. A contract pharmacy relationship that isn’t monitored closely, a TPA agreement with unclear terms, or a manufacturer restriction that changes without anyone noticing can each quietly erode the savings 340B is supposed to deliver.
340B compliance was already a meaningful lift before recent changes added more weight. The Drug Supply Chain Security Act has added new traceability requirements across the pharmaceutical supply chain. New pricing guidelines for medications like epinephrine and insulin now require covered entities to provide these drugs at or under 340B acquisition cost.† And cuts to grant funding are landing at the same time, putting financial pressure on the very organizations that depend most on 340B savings to stay sustainable.
None of these pressures are optional to manage. They’re compounding on top of a program that most FQHCs were already tracking manually, with a lean administrative team that has a long list of other compliance obligations competing for the same attention.
For an FQHC with a small compliance or finance team, 340B contract pharmacy relationships, TPA agreements, and manufacturer restrictions often live in a mix of spreadsheets, email threads, and whatever documentation the original contracting process left behind. Nobody chose that approach because it works well. It’s what’s left when a lean team is asked to manage a genuinely complex, multi-vendor compliance program without a system built to support it.
That’s a familiar pattern for organizations doing essential work with limited administrative bandwidth: the risk isn’t a lack of effort, it’s a lack of infrastructure built for the actual complexity of what’s being managed.
Managing 340B well means treating contract pharmacy agreements, TPA relationships, and manufacturer terms as what they are: a connected set of contracts with real compliance weight, not a collection of separate administrative tasks. That means knowing which agreements are current, what each one requires, and having a clear, current record ready if a HRSA audit or a manufacturer compliance review asks for it, rather than assembling that picture from scratch under pressure.
Ntracts brings 340B-related contracts, vendor relationships, and compliance obligations into the same connected solution as the rest of an FQHC’s governance, not a separate, manually tracked program sitting apart from everything else. Contract pharmacy agreements, TPA relationships, and their compliance requirements live alongside policy and audit readiness, so a lean team isn’t managing 340B’s complexity with fewer resources than the program requires.
That’s what turns a program built to sustain the mission into one that doesn’t quietly put it at risk.
*USC Schaeffer Center, background on the 340B Drug Pricing Program, 2025.
**National Association of Community Health Centers, health center program scope and patient demographics, 2022-2026 reporting.
***Industry reporting on FQHC 340B contract pharmacy models and associated limitations, 2024-2026.
†Industry reporting on 340B compliance pressures, including DSCSA requirements and drug pricing guideline changes, 2026.